This feature highlights changes in clinical trial organizations’ personnel.
Adaptimmune Therapeutics has named Elliot Norry as the company’s new senior vice president and chief medical officer. Norry will be transitioning from his previous head of clinical safety and pharmacovigilance role with Adaptimmune. Previously, Norry was the safety development leader and chair of the hepatic safety panel at GlaxoSmithKline. Adaptimmune has also named Mark Dudley as head of early stage development, and Dennis Williams will now lead late-stage development. Additionally, Adaptimmune has promoted Joanna Brewer to head of allogeneic research.
Boston-based precision genetic medicine company Akouos has appointed Morgan Molloy to the role of chief corporate development officer. Previously, Molloy was chief commercial officer at Enzyvant. Akouos has also appointed Karoline Shair to the position of senior vice president, general counsel and corporate secretary. Shair was most recently the vice president and head counsel of the intellectual property program portfolio at Biogen.
Avellino Labs has appointed Chris Lehman to the role of chief financial officer. Lehman joins the company after serving as chief financial officer for Eureka Therapeutics.
Charles Gayer has been named BioCryst Pharmaceuticals’ new chief commercial officer. Prior to joining BioCryst, Gayer held U.S. and global commercial leadership roles in rare disease categories at Grifols and Talecris Biotherapeutics. BioCryst has also named Allen Hodge the firm’s newest vice president and general manager for the U.S. Hodge comes to BioCryst from Array Biopharma.
Germany-based BioNTech has appointed Ryan Richardson to the role of chief strategy officer and managing director, a promotion from his previous role as the company’s head of corporate development & strategy. Richardson was an executive director on the global healthcare investment banking team at J.P. Morgan's London office prior to joining BioNTech.
Casma Therapeutics has announced the appointments of Christian Grimm, professor of molecular pharmacology at the department of pharmacology and toxicology at the Ludwig-Maximilians-University Munich in Germany, and Martin Kampmann, associate professor at the University of California at San Francisco, to the firm’s scientific advisory board.
Cynosure has named Todd Tillemans, former president at Hershey’s U.S. flagship business, the firm’s newest CEO. Jorge Pinedo has also joined Cynosure as the company’s executive vice president, international. Previously, Pinedo was a senior vice president at Johnson & Johnson.
Carolyn Porter has been named CytoSeek’s newest CEO and director. Porter joins the discovery-stage biotech company after previously serving as the chief business officer of OxStem.
Dyne Therapeutics has tapped Molly White as the company’s new vice president of medical communications and advocacy. White previously served as the CEO of Myotonic before joining Dyne.
Lewis Cameron has joined Ergomed as the firm’s chief operating officer. Previously, Cameron was the head of global clinical development at Covance in Spain.
David Hallett has been appointed to the role of chief operating officer and head of drug discovery at Exscientia. Hallett was most recently an executive vice president at Evotec.
Neuronetics has named Andrew Macan the company’s new senior vice president, general counsel, chief compliance officer and corporate secretary. Most recently, Macan held the roles of senior vice president, general counsel and corporate secretary at U.S. Silica Holdings.
Donald A. Middlebrook has been named Nevro’s vice president of clinical, regulatory and quality. Most recently, Middlebrook was a regulatory and clinical affairs consultant for St. Jude Medical.
Maureen Merrifield will now serve as vice president of clinical and regulatory affairs at Pharmatech Associates. Prior to joining Pharmatech, Merrifield was director of regulatory and strategic development at Clinipace Worldwide.
Yuichiro Haruyama, senior strategic officer at Sumitomo Dainippon Pharma, will now be the company’s senior strategic officer of the North America Sumitovant business.
Ricky Sharma has been appointed to the role of vice president of clinical affairs at Varian. Previously, Sharma was the chair of radiation oncology at University College London, where he still serves as honorary clinical professor.